Teplizumab-mzwv (Tzield) Coverage Policy
Customize your policy alerts
Sign up for blue cross blue shield - tennessee Policy ID_CHS_56782026_1026 alerts
Get alerted when Policy ID_CHS_56782026_1026 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical necessity criteria for Tzield to delay the onset of Stage 3 type 1 diabetes or delay decline in endogenous insulin production in recently diagnosed Stage 3 type 1 diabetes, subject to specified clinical, age, prescriber, documentation, and treatment-course requirements.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.